{"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"191"}],"units":"Participants"}],"groups":[{"description":"Non-cryopreserved LN-144 (Gen 1 infusion product) (Closed)","id":"BG000","title":"Cohort 1"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)","id":"BG001","title":"Cohort 2"},{"description":"Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b) (Closed)","id":"BG002","title":"Cohort 3"},{"description":"Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)","id":"BG003","title":"Cohort 4"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"66"},{"groupId":"BG004","value":"140"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"23"},{"groupId":"BG004","value":"39"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Initial Treatment"},{"categories":[{"measurements":[{"groupId":"BG002","value":"0"},{"groupId":"BG004","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG002","value":"11"},{"groupId":"BG004","value":"11"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG002","value":"1"},{"groupId":"BG004","value":"1"}],"title":">=65 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}],"units":"Participants"}],"title":"Retreatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data prior to initial TIL treatment are presented in the retreatment period for Cohort 3","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"37","upperLimit":"72","value":"52"},{"groupId":"BG001","lowerLimit":"20","upperLimit":"79","value":"55"},{"groupId":"BG003","lowerLimit":"25","upperLimit":"74","value":"58"},{"groupId":"BG004","lowerLimit":"20","upperLimit":"79","value":"56"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Initial Treatment"},{"categories":[{"measurements":[{"groupId":"BG002","lowerLimit":"29","upperLimit":"66","value":"52"},{"groupId":"BG004","lowerLimit":"29","upperLimit":"66","value":"52"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}],"units":"Participants"}],"title":"Retreatment"}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","populationDescription":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data prior to initial TIL treatment are presented in the retreatment period for Cohort 3","title":"Age, Continuous","unitOfMeasure":"Years"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"44"},{"groupId":"BG004","value":"84"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"45"},{"groupId":"BG004","value":"95"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Initial Treatment"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"9"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}],"units":"Participants"}],"title":"Retreatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data prior to initial TIL treatment are presented in the retreatment period for Cohort 3","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"10"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"85"},{"groupId":"BG004","value":"161"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"8"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Initial Treatment"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"10"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}],"units":"Participants"}],"title":"Retreatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data prior to initial TIL treatment are presented in the retreatment period for Cohort 3","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"85"},{"groupId":"BG004","value":"172"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Initial Treatment"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"9"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}],"units":"Participants"}],"title":"Retreatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data prior to initial TIL treatment are presented in the retreatment period for Cohort 3","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"55"},{"groupId":"BG004","value":"134"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"France"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"19"},{"groupId":"BG004","value":"19"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Germany"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"13"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Spain"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"Switzerland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"7"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"67"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"89"},{"groupId":"BG004","value":"179"}],"units":"Participants"}],"title":"United Kingdom"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data prior to initial TIL treatment are presented in the retreatment period for Cohort 3","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"8"}],"title":"United States"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"France"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"2"}],"title":"Germany"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}],"title":"United Kingdom"}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"12"}],"units":"Participants"}]}],"description":"Region of enrollment for retreatment","paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"This is the region of enrollment for retreatment","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"The Safety Analysis Set is defined as patients who received the lifileucel infusion. Cohort 3 patients had progressed following initial treatment in Cohorts 1, 2, 4 and then were retreated with a second TIL regimen. Data are captured in the retreatment period for Cohort 3"}